Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KVD 824

Next Previous
Drug Profile

KVD 824

Alternative Names: KVD-824

Latest Information Update: 06 Oct 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vantia Therapeutics
  • Developer KalVista Pharmaceuticals
  • Class Eye disorder therapies; Skin disorder therapies; Small molecules; Vascular disorder therapies
  • Mechanism of Action Plasma kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hereditary angioedema
  • Discontinued Diabetic macular oedema

Most Recent Events

  • 04 Oct 2022 Adverse events data from the phase II KOMPLETE trial in Hereditary angioedema released by KalVista Pharmaceuticals
  • 04 Oct 2022 KalVista Pharmaceuticals terminates the phase II KOMPLETE trial in Hereditary angioedema (Prevention) in Puerto Rico, United Kingdom, Macedonia, New Zealand, Italy, Hungary, Germany, France, Czech Republic, Canada, Australia, Bulgaria and USA (PO) due to observation of liver enzyme elevations in multiple patients (NCT05055258) (EudraCT2021-000136-59)
  • 28 Apr 2022 No recent reports of development identified for phase-I development in Hereditary-angioedema(Prevention) in United Kingdom (PO, Capsule)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top